Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target ...

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other best mid cap growth stocks. 50 Basis Point Reduction: Exaggeration or Hidden Benefit ...

Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other best revenue growth stocks to buy according to analysts. The Fed recently ...

In trading on Thursday, shares of Sarepta Therapeutics Inc (Symbol: SRPT) crossed below their 200 day moving average of $125.11, changing hands as low as $124.49 per share. Sarepta Therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our P/B Growth Investor model based on the published ...

In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other best mid cap growth stocks. Recent discussions among financial strategists ...